Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label Study to Evaluate the Safety of Golodirsen in Non-Ambulant Patients With Duchenne Muscular Dystrophy

Next Previous
X
Search
Trial Profile

An Open-Label Study to Evaluate the Safety of Golodirsen in Non-Ambulant Patients With Duchenne Muscular Dystrophy

Status: Discontinued
Phase of Trial: Phase IV

Latest Information Update: 22 May 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Golodirsen (Primary)
  • Indications Duchenne muscular dystrophy
  • Focus Adverse reactions

    • Most Recent Events

    • 13 May 2021 Status changed from active, no longer recruiting to discontinued, because the Sponsor has decided to focus their resources on other areas of therapy.
    • 04 Mar 2021 Status changed from suspended to active, no longer recruiting.
    • 01 Mar 2021 Status changed from recruiting to suspended as the Sponsor has decided to focus on other areas of therapy and would like to pull the resources from this study to other studies

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top